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The R47H coding variant of the triggering receptor expressed onmyeloid cells-2 (TREM2)
increases the risk of Alzheimer’s disease (AD) similar to apolipoprotein E4. TREM2
R47H has recently been shown to have impaired binding to damage-associated lipid
or apolipoprotein ligands. However, it is not known how this R47H variant affects
the biochemical characteristics of TREM2 and alters the pathogenesis of AD. We
previously reported that TREM2-R47H has a slightly different glycosylation pattern from
wild-type. A more detailed characterization in our present study confirms that TREM2
R47H has an altered glycosylation pattern and reduced stability. TREM2 R47H shows
different glycosylation profiles from analysis using monensin or kifunensine treatment
which were confirmed by mass spectrometry. The solubility of TREM2 R47H and its
cleaved products such as intracellular domain (ICD) is also decreased, increasing its
proteasomal and lysosomal degradation. The different biochemical characteristics of
TREM2 R47H, including glycosylation, solubility and processing, may offer insights into
a future therapeutic strategy for AD.
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INTRODUCTION
Myeloid cells such as microglia, dendritic cells, osteoclasts, and macrophages express triggering
receptor expressed onmyeloid cells-2 (TREM2) which belongs to the immunoglobulin superfamily.
TREM2 is a type 1 membrane protein consisted of an extracellular immunoglobulin-like domain
and a short cytoplasmic tail (Figure 1A). TREM2 may work in myeloid cells, most presumably
osteoclasts and microglial cells, both of which are included in brain function and bone modeling
(Cella et al., 2003). Microglial TREM2 also has an important role in removing neural debris in the
brain lesion (Lucin et al., 2013).
The R47H variant of TREM2 was recently revealed to be associated with the progression of late-
onset Alzheimer’s disease (AD) by a genome-wide-association study (GWAS, Jiang et al., 2013).
TREM2 is increased in the microglia in AD transgenic mouse models (Frank et al., 2008; Melchior
et al., 2010). A fronto-temporal dementia (FTD)-like syndrome without bone pathology was also
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FIGURE 1 | Differences in the wild-type and R47H variant TREM2
expression patterns. (A) Schematic diagram of the triggering receptor
expressed on myeloid cells-2 (TREM2) showing 2 N-glycosylation sites on the
immunoglobulin (IG) domain of TREM2 and mutation site R47H. The
hemagglutinin (HA)-tag was added to the C-terminus. SP, signal peptide. TM,
transmembrane domain. (B) HeLa cells were transfected with wild-type
TREM2 and its R47H mutant and immunoblotted with HA antibody. A similar
thick band of ∼28 kDa was found for both expressed proteins (c) with different
patterns found for the upper bands (a,b) and thick lower bands (d). These data
represent the mean ± S.E. from three independent experiments. *P < 0.05.
recently reported to be associated with several TREM2
mutations (Guerreiro et al., 2013). TREM2 mutations have
also been identified as risk factors for Parkinson’s disease
(PD), amyotrophic lateral sclerosis (ALS), and FTD (Rayaprolu
et al., 2013; Borroni et al., 2014; Cady et al., 2014; Cuyvers
et al., 2014). TREM2 mutations such as Y38C and T66M
are related to a genetic disease known as Nasu-Hakola
disease [NHD, polycystic lipomembranous osteodysplasia with
sclerosing leukoencephalopathy (PLOSL)] (Soragna et al., 2003).
NHD is an autosomal, recessive disorder which occurs in
families from Finland and Japan. It shows progressive, presenile,
inflammatory neurodegeneration, and the formation of bone
cysts. Severe brain lesions were also previously identified in mice
with the same mutations (Colonna, 2003; Kaifu et al., 2003).
Several different ligands for TREM2 have been reported
including apolipoprotein E (Atagi et al., 2015; Bailey et al.,
2015), lipids exposed upon axonal injury (Poliani et al., 2015),
nucleic acids released from dying cells (Kawabori et al., 2015)
and damage-associated molecular signatures found on bacteria
(Daws et al., 2003; N’Diaye et al., 2009). Interestingly, the AD-
associated TREM2 R47H variant has impaired binding to the
apolipoprotein E or injury-associated lipids (Atagi et al., 2015;
Bailey et al., 2015; Poliani et al., 2015). However, it is still
unknown how this impairment occurs, or how this may relate
to AD pathogenesis. Hence, although it is now known that the
glycosylation and trafficking of TREM2 is impaired by NHD-
associated mutations such as Y38C and T66M (Kleinberger
et al., 2014; Park et al., 2015), it is not yet clear how the
biochemical characteristics of TREM2 are affected by the AD-
associated R47H variant. Although we previously reported that
TREM2-R47H shows subtle glycosylation pattern changes (Park
et al., 2015), a more detailed characterization of this variant is
necessary to provide further insights into the molecular basis
for AD pathogenesis. Hence, we here compared the biochemical
characteristics of TREM2 R47H and wild-type TREM2 in more
detail to further elucidate the disruption to TREM ligand binding
and promotion of AD pathogenesis by this variation.
METHODS
Reagents
MG132 was obtained from Calbiochem (San Fransico, CA,
USA). Monensin, kifunensin, cycloheximide, bafilomycin A1
were sourced from Sigma-Aldrich (St Louis, MO). All plasmids
used for cloning were obtained from Cosmo Genetech Co. Ltd.
Plasmid Constructions and Antibodies
Human TREM2 construct was purchased from Sino Biological
Inc., BDA, Beijing and pcDNA5-FRT/TO-HA was obtained from
Dr. SW Kang Bio-Medical Institute of Technology. Wild-type
human TREM2 (TREM2 wild-type) was inserted into Hind-III
and Xho-I sites of pcDNA5-FRT/TO-HA. A point mutation in
TREM2 was generated to substitute Arg with His at position
47 and thus produce the R47H variant. These modified TREM2
mutations of cDNAs were PCR-amplified and sub-cloned into
the pcDNA5-FRT/TO-HA vector. All constructs was verified by
DNA sequencing.
Cell-Culture Analysis
HeLa cells were maintained in DMEM (HyClone Laboratories,
UT, USA) supplemented with 10% fetal bovine serum
(HyClone Laboratories) and were incubated in 5% CO2 at
37◦C. All experiments involving transient transfection were
performed using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA) in accordance with the manufacturer’s instructions. Cells
transfected with the wild-type and R47H variant of TREM2 were
incubated in antibiotic-free DMEM media for 4 h, after which
the media was replaced with DMEM supplemented with FBS.
Protein Extraction and Analysis
Cell lysates were prepared in a buffer containing 1% SDS, 100
mM Tris-HCl, and pH 8.0 and were boiled for 5 min. To
obtain Triton X-100-soluble and -insoluble fractions for the
analysis of protein solubility, cells were incubated with Triton-
lysis-buffer [1% Triton X-100, 20 mM HEPES pH7.5, 150 mM
NaCl, protease inhibitor cocktail (Calbiochem)] for 15 min on a
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rocking platform as previously described (Kang et al., 2006). After
centrifugation, the supernatant (Triton-soluble fraction) was
collected. The Triton insoluble fraction (pellet) was resuspended
in SDS-lysis-buffer (1% SDS, 100 mM Tris-HCl, and pH 8.0).
Both fractions were reconstituted to equal volumes and analyzed
by western blotting as described below.
To analyze the digitonin fraction, cells were incubated with
0.75% digitonin solution for 5 min on ice as previously described
(Kang et al., 2006). Parts of the lysate were mixed with the sample
buffer for the preparation of total cell sample and some of lysate
was centrifuged at 800 g for 5 min. Supernatant (cytosol fraction)
was collected and pellet were incubated with Triton-lysis-buffer
(1%Triton X-100, 20mMHEPES pH 7.5, 150mMNaCl, protease
inhibitor cocktail) for 5 min on ice. The pellet incubated with
Triton-lysis buffer were centrifuged at 800 g for 5 min. Some
of supernatant was collected for the membrane fraction and
the remainder was centrifuged at 13,000 rpm for 30 min (the
supernatant contained the soluble membrane fraction and the
pellet the insoluble membrane fraction).
Western Blotting
For western blotting, protein lysates from HeLa cells transfected
with either the TREM2 wild-type or R47H mutant construct
were fully solubilized with 1% SDS, and 100 mM Tris-
HCl, pH 8.0. Protein concentrations were measured using
the Bradford method. Equal amounts of protein were mixed
with the sample buffer (62.5 mM Tris-HCl [pH 6.8], 1%
[w/v] sodium dodecyl sulfate [SDS], 2.5% [v/v] glycerol, 0.5%
[v/v] β-mercaptoethanol, and bromophenol blue), boiled at
100◦C for 5 min, and stored at −20◦C until use. Proteins
were resolved by SDS-polyacrylamide gel electrophoresis at a
constant voltage (100 V) and were subsequently transferred
to polyvinylidene difluoride membranes (pore size, 0.2 mm;
BioRad, CA) at 100 V for 1.5 h. After 1 h incubation in
blocking PBST buffer (0.1% [v/v] Tween-20) containing 2% (w/v)
bovine serum albumin and 2% (v/v) normal horse serum, blots
were incubated with primary antibodies overnight at 4◦C. Blots
were then washed in PBST buffer, incubated with horseradish,
peroxidase-conjugated, anti-IgG (1:5000; Pierce, Rockford, IL),
and visualized using enhanced chemiluminescence reagents
(Amersham, Arlington Heights, IL) and X-ray film. The primary
antibodies used in the immunoblotting were rat anti-HA (1:5000;
Roche, Mannheim, Germany), mouse anti-GRP78 (1:1000, BD
Transduction LaboratoriesTM, California, CA, USA), rabbit anti-
phospho-eIF2α (Ser51) (1:1000, Cell Signaling Technology,
Danvers, MA), rabbit anti-phospho PERK(Thr981) (1:100, Santa
Cruz, CA), rabbit anti-PERK(H-300) (1:100, Santa Cruz, CA),
and mouse anti-β-actin (1:10,000; Sigma-Aldrich).
In-gel PNGase F Digestion
Coomassie blue-stained protein bands were excised from the ge1,
chopped into 1 mm3 pieces and washed repeatedly in 100 mM
ammonium bicarbonate buffer for 10min and then in acetonitrile
for 10 min to enable enzyme penetration. The pieces were then
dried thoroughly in a vacuum centrifuge and rehydrated in
200 mM ammonium bicarbonate containing 1 µL (or 500 U)
of peptide N-glycosidase F (New England Biolabs). Enzymatic
deglycosylation was then performed at 37◦C for 16 h in the water
bath. At the end of the digestion, the N-glycan supernatant was
drawn out from the gel pieces and the extracted glycans were
dried in a vacuum centrifuge.
Nano-LC/MS Analysis and Data Processing
MS analysis was performed in accordance with the optimized
procedures published by Hua et al. (2013). Aqueous glycan
solutions were injected by autosampler onto a chip-mounted
nano-LC column (Agilent Technologies), consisting of a 9 ×
0.075 mm i.d. enrichment column and a 43 × 0.075 mm i.d.
analytical column. Both columns were packed with 5 µm porous
graphitized carbon as the stationary phase. A rapid glycan elution
gradient was delivered to the analytical column at 0.3 µL/min
using solutions of (A) 3.0% acetonitrile and 0.1% formic acid
(v/v) in water, and (B) 90.0% acetonitrile and 0.1% formic
acid (v/v) in water, ramping from 0 to 44% B solution over
30 min. Remaining non-glycan compounds were flushed out
with 100% B solution prior to re-equilibration. MS spectra
were acquired via a TOF MS detector (model 6530, Agilent
Technologies) in positive ionization mode over a mass range of
m/z 500−2000 with an acquisition time of 1.5 s per spectrum.
Following data acquisition, raw LC/MS data were processed
using the Molecular Feature Extractor algorithm included in
the MassHunter Qualitative Analysis software (Version B.6.00
SP1, Agilent Technologies). Using expected isotopic distribution
and charge state information, extracted ion chromatograms were
combined to create extracted compound chromatograms (ECCs)
representing the summed signal from all ion species associated
with a single compound (e.g., the doubly protonated ion, the
triply protonated ion, and all associated isotopologues). Thus,
each individual ECC peak could be taken to represent the total
ion count associated with a single distinct compound. Each
ECC peak was matched by accurate mass to a comprehensive
library of all possible complex, hybrid, and high mannose
glycan compositions based on known biosynthetic pathways and
glycosylation patterns (Kronewitter et al., 2009). Deconvoluted
masses of each ECC peak were compared against theoretical
glycanmasses using a mass error tolerance of 10 ppm. As samples
originated from human cell lines, only glycan compositions
containing hexose (Hex), N-acetylhexosamine (HexNAc), fucose
(Fuc), and N-acetylneuraminic acid (NeuAc) were considered.
Statistical Analysis
Western bands were measured and analyzed with Image J
software. Data are presented as mean ± SEM from at least
triplicate experiments. Statistical analyses were performed using
GraphPad Prism 5.0 software using an unpaired t-test or two-way
ANOVA; ∗∗∗P < 0.001; ∗∗P < 0.01; ∗P < 0.05.
RESULTS
Differences in the Wild-Type and R47H
Variant TREM2 Expression Patterns
To investigate whether, and how, the R47H variant of TREM2
reported in AD (Soragna et al., 2003; Jiang et al., 2013) affected
the trafficking of TREM2, the R47H mutation was introduced
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into TREM2 and the variant protein was expressed in HeLa
cells (Figure 1B and Supplementary Figure 1). Western blots
confirmed that the expression patterns of wild-type TREM2 and
R47H mutants differed as we previously observed (Park et al.,
2015). The expectedmolecular weight of TREM2 is about 25 kDa.
Both the wild-type and R47H variant of TREM2 showed a thick
band of ∼28 kDa (Figure 1B, c) with the N-glycosylated form
detectable in the ER. The upper 30∼40 kDa bands denote the
glycosylated forms in the Golgi. The uppermost bands of R47H
at about 40 kDa were more intense than those of the wild-type
protein (Figure 1B, a), although the upper bands of R47H at
about 30 kDa were at a lower intensity than wild-type (Figure 1B,
b). the C-terminal fragment (CTF) of R47H at about 10 kDa was
less intense than its wild-type counterpart (Figure 1B, d).
Increased Terminal Glycosylation of the
TREM2 R47H Variant in the Trans-Golgi
Since the upper bands for TREM2 on an immunoblot reflect
its glycosylation status (Park et al., 2015), we suspected that the
different expression patterns of wild-type TREM2 and its R47H
variant (Figure 1B) are due to glycosylation changes. Hence,
we treated cells with monensin (10 µM, 8 h) which blocks the
transport from the medial to the trans cisternae of the Golgi stack
and prevents terminal glycosylation (Griffiths et al., 1983). The
highest western band (Figure 2A, a), which is more prominent
for TREM2 R47H, is a monensin-sensitive glycosylated form
but the lower band (Figure 2A, b), which is more prominent
for the wild type protein, is resistant to monensin. Thus, the
mobility difference between wild-type and R47H variant of
TREM2 reflects the differences in their glycan structures.
To further analyze the glycosylation characteristics of TREM2,
we treated cells with kifunensin, a mannosidase I inhibitor that
prevents the trimming of mannose residues from high mannose
N-glycans, thereby preventing the synthesis of complex N-
glycans that are acceptors for α1–3-fucosyltransferases (Elbein
et al., 1990; Yago et al., 2003). Kifunensine treatment decreased
the intensity of the upper bands (Figure 2B, a and b), indicating
that the higher TREM2 bands of ∼30–45 kDa (Figure 2B, a and
b) represent the addition of complex oligosaccharide chains to
this protein in the Golgi and the thick, main band at about 28
kDa (Figure 1B, c) represents N-linked glycosylation with high
mannose in the ER, further confirming our previous findings
(Park et al., 2015).
Different Glycosylation Profiles of
Wild-Type TREM2 and the R47H Variant
To further investigate the glycosylation differences between
the wild-type TREM2 and the R47H variant, the N-glycans
FIGURE 2 | Increased terminal glycosylation of the TREM2 R47H variant in the trans-Golgi. (A) After monensin (10 µM) treatment for 8 h, the highest bands
(a) for wild type TREM2 and the R47H variant were decreased in intensity, whereas the middle bands (b) were increased. (B) After kifunensin (2 µg/µl) treatment for
4 h, the intensity of the highest bands (a) for wild type TREM2 and the R47H variant were decreased. These data represent the mean ± S.E. from three independent
experiments. *P < 0.05, **P < 0.01.
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FIGURE 3 | Different glycosylation profiles of wild-type TREM2 and the R47H variant. (A) Extracted compound chromatograms (ECCs) of N-glycans found in
wild-type TREM2 (top) and the R47H variant (bottom). Colors denote different glycan classes. (B) Bar graph of relative abundances and standard errors associated
with complex, hybrid, and high mannose type N-glycans (to indicate the statistically significant differences between wild-type TREM2 and the R47H variant, the t-test
p-values are shown.) (C) Relative abundances and standard errors associated with the undecorated complex type glycans. (D) Relative abundances and standard
errors associated with the sialylated and fucosylated complex type glycans.
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released from these proteins (Figure 1B, a,b) were analyzed
by nano-LC/MS. Figure 3A shows ECCs of the N-glycans
found in wild-type TREM2 (top) and TREM2 R47H (bottom),
respectively. Each peak in Figure 3A represents individual
N-glycan species, color-coded according to biosynthetic class
(high mannose, undecorated complex/hybrid, fucosylated
complex/hybrid, sialylated complex/hybrid, or fucosylated-
sialylated complex/hybrid). Approximately 100 N-glycan
compound peaks with 38 distinct N-glycan compositions were
identified in wild-type TREM2, whereas over 110 N-glycan
compound peaks with over 45 distinct N-glycan compositions
were identified in the TREM2 R47H variant. Casual inspection
revealed that N-glycosylation of wild-type TREM2 is different
from that of TREM2 R47H in terms of complex/hybrid N-
glycans which were not detectable in wild-type TREM2 at
the retention time of 22–28 min (red box). To more precisely
FIGURE 4 | Decreased solubility of TREM2 R47H. (A) Protein samples from HeLa cells expressing wild-type TREM2 and its R47H variant were fractionated with
detergent. TREM2 R47H was found to be increased in the detergent-insoluble fractions. Major histocompatibility complex (MHC)-I was used as a loading control for
verification of fractionation. (T, total fraction; S, soluble fraction; I, insoluble fraction). (B) HeLa cells expressing wild-type TREM2 and its R47H variant were treated with
MG 132 (10 µM) for 16 h. The TREM2 R47H levels were elevated compared to wild-type. (C) Following bafilomycin A1 (Baf A1) (25 nM) treatment for 16 h, TREM2
R47H expression was increased compared to wild-type. (D,E) The intracellular domain (ICD) bands of TREM2 are increased by treatment with MG132. Cropped
images from the original blot (Supplementary Figure 2) are displayed here. Following bafilomycin A1 treatment, the CTF and ICD bands of TREM2 R47H are increased
compared to wild-type. These data represent the mean ± S.E. from three independent experiments. *P < 0.05.
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examine the glycosylation differences between wild-type and
TREM2 R47H, the glycans detected for both proteins were
quantified using the chromatogram peak areas. Figure 3B
shows a bar graph of the relative abundances associated with
each glycan type in R47H vs. wild-type TREM2. Glycans were
grouped into high mannose type, undecorated complex/hybrid,
fucosylated complex/hybrid, sialylated complex/hybrid, and
fucosylated-sialylated complex/hybrid type. The high mannose
type glycans were found in high abundance in both wild-
type and TREM2 R47H, accounting for ∼80% of the total
glycans. Overall, the non-high mannose type glycan, which
is less abundant in TREM2, was elevated in TREM2 R47H.
Moreover, we confirmed using a t-test that the levels of
undecorated complex/hybrid type glycans (p = 0.012) and
fucosylated-sialylated complex/hybrid type glycans (p = 0.021)
had statistically significant differences between wild-type and
TREM2 R47H.
To more precisely quantify the differences between
wild-type and TREM2 R47H, the relative abundances of
individual glycans were compared. The profiles of the N-
glycan structures found in both wild-type and TREM2 R47H
are shown in Figure 3C (undecorated complex/hybrid type
glycans) and Figure 3D (fucosylated-sialylated complex/hybrid
type glycans). Wild-type TREM2, in turn, was readily
distinguishable from TREM2 R47H by elevated levels of
glycans consisting of [Hex]3−6[HexNAc]3−5[Fuc]1−2[NeuAc]1.
Interestingly, all glycans are biosynthetically highly
related, each differing from the next by few
monosaccharides.
Decreased Solubility of TREM2 R47H
To further investigate the biochemical differences between wild-
type and TREM2 R47H, we tested the solubility of these
proteins in triton-X100 as previously described (Kang et al.,
2006). TREM2 R47H was increased in the insoluble fractions
compared to the wild-type product (Figure 4A), suggesting the
decreased solubility by R47H variant. We next treated cells
with MG132, a proteasomal inhibitor, to block proteasomal
degradation. TREM2 R47H was more elevated after MG132
treatment compared to wild-type (Figure 4B), indicating that
this variant is unstable and degraded via the ER associated
degradation (ERAD) pathway (Kroeger et al., 2009; D’Souza
et al., 2013). We also treated cells with bafilomycin A1, a v-
ATPase inhibitor, to block lysosomal degradation (Cho et al.,
FIGURE 5 | Increased half-life of TREM2 R47H. (A) HeLa cells transfected with wild-type TREM2 and the R47H variant were treated with cycloheximide (5 µg/µl)
for the indicated times. TREM2 R47H decreased more slowly compared with wild-type. (B) The intensity of each band was measured using Image J and relative
intensities are plotted. The data represent the mean ± S.E. from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.005. (C) Protein samples from HeLa
cells expressing various types of TREM2 were fractionated with digitonin. Both wild-type and TREM2 R47H were present in the membranous organelle fraction (M).
This fraction was further fractionated into membrane soluble (MS) and membrane insoluble (MI) fractions. Unglycosylated bands of TREM2 (arrow) were found only in
the membranous fractions and not in the cytosolic (c) fraction.
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2014). TREM2R47Hwas againmore elevated after this treatment
compared to wild-type (Figure 4C), again indicating that this
variant is unstable and is largely degraded by lysosomes. The
intracellular domain (ICD) of TREM2, which is generated after
cleavage by secretases (Wunderlich et al., 2013; Kleinberger et al.,
2014), was also increased in MG132- or bafilomycin A1-treated
cells (Figures 4D,E).
Increased Half-Life of TREM2 R47H
The half-life of TREM2 was tested in transfected cells exposed
to the protein synthesis inhibitor cycloheximide. In the wild-
type TREM2 transfected cells, the exogenously expressed
protein decreased very rapidly after cycloheximide treatment
(Figures 5A,B), indicating that TREM2 is rapidly degraded
under normal conditions. However, in the TREM2 R47H-
transfected cells, the levels of the variant protein decreased
more slowly after cycloheximide treatment compared to wild-
type (Figures 5A,B), indicating a longer half-life. Interestingly,
this feature was apparent in the ER forms of TREM2 R47H
(Figure 5A, b and c, Figure 5B) (Park et al., 2015), but not so
for the variant protein in the Golgi (Figure 5A, a, Figure 5B),
suggesting that the R47H mutant has increased resistance to
degradation in ER rather than to degradation after trafficking to
the Golgi. Since the unglycosylated bands of TREM2 (Figure 5A,
c) can reflect two forms, either in the ER or in the cytosol,
we fractionated cells into cytosolic and membranous organelles,
and further into soluble and insoluble membranous organelles
FIGURE 6 | The TREM2 R47H variant does not cause ER stress
induction. Western blots of HeLa cells transfected with wild-type TREM2 and
the R47H variant indicated no significant changes in ER stress markers such
as GRP78, phosphorylated eIF2α, and phosphorylated PERK. Cropped
images from the original blot (Supplementary Figure 3) are displayed here.
(Figure 5C) as previously described (Kang et al., 2006). The
results of this experiment indicated that the unglycosylated
TREM2 form (Figure 5A, c) is in the ER membrane (Figure 5C,
arrow) and not in the cytosol after retrotranslocation from
the ER.
DISCUSSION
TREM2 mutations are associated with neurological disorders
(Bird, 2013; Giraldo et al., 2013; Guerreiro et al., 2013; Luis
et al., 2014), although it is not well known how TREM2
contributes to these diseases. We found in our current analyses
that the AD-associated R47H variant of TREM2 has increased
terminal glycosylation with complex oligosaccharides in the
Golgi apparatus and decreased solubility. This may affect its
ligand binding and receptor function and contribute to AD
pathogenesis (Figure 7).
FIGURE 7 | Putative model of the role of TREM2 R47H in AD
pathogenesis. TREM2 is normally trafficked from the ER to the Golgi and
plasma membrane for appropriate glycosylation in the Golgi and quality control
in the ER. The AD-associated R47H variant of TREM2 shows terminal
glycosylation impairment, which may disrupt ligand binding, TREM2
proteolysis or phagocytosis of microglia. TREM2 R47H is unstable and
resistant to proteasomal degradation.
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Since arginine 47 is located in the extracellular region of
TREM2 and the R47H mutation changes the glycosylation
status of the extracellular region of TREM2 (Figures 1–3),
this base substitution can alter the binding of TREM2 to its
ligands, its receptor function and its processing by proteases,
all of which may underlie the molecular pathways by which
this variant contributes to the pathogenesis of AD. Several
different ligands for TREM2 have been reported previously
including apolipoprotein E (Atagi et al., 2015; Bailey et al.,
2015), lipids exposed upon axonal injury (Poliani et al., 2015),
nucleic acids released from dying cells (Kawabori et al., 2015)
and damage-associated molecular signatures found on bacteria
(Daws et al., 2003; N’Diaye et al., 2009). Interestingly, the AD-
associated TREM2 R47H variant shows impaired binding to
apolipoprotein E or injury-associated lipids (Atagi et al., 2015;
Bailey et al., 2015; Poliani et al., 2015). Hence, we speculate
that the glycosylation status changes we observed herein for the
R47H variant (Figures 1–3) could explain the ligand binding
differences between wild-type TREM2 and TREM2 R47H (Atagi
et al., 2015; Bailey et al., 2015; Poliani et al., 2015).
We and others have previously reported that the tyrosine-
38 and threonine-66 residues of TREM2, which are contained
within the NHD (Soragna et al., 2003), are critical for the
glycosylation of this protein with complex oligosaccharides in
the Golgi. This pathway is important for the surface localization
of TREM2 and its processing by secretases which facilitate its
normal functions (Kleinberger et al., 2014; Park et al., 2015).
Y38C and T66M mutations in TREM2 produce prominent
glycosylation pattern differences and impairment of trafficking
to the plasma membrane (Kleinberger et al., 2014; Park et al.,
2015). In our present study, we observed slight differences in the
N-glycosylation of TREM2 R47H with complex oligosaccharides
(Figure 1), compared with the NHD-associated Y38C and T66M
variants. This difference in the glycosylation pattern seems to
reflect the resulting disease severity such that NHD mutations
can lead to early-onset disease and that AD is typically a late-
onset disease.
TREM2 R47H has a lower solubility than wild-type
(Figure 4), which could be due to its altered glycosylation
status (Figures 1–3) or possible structural changes which have
not yet been elucidated. This reduced solubility may cause the
proteasomal and lysosomal degradation systems to become
more active in order to maintain the normal steady status level
of TREM2 (Figures 4B,C). However, for certain conditions
that overload the normal capacity of proteasomal or lysosomal
degradation, the lower solubility of TREM2 may worsen the
situation, resulting in the ER stress or lysosomal degradation
problems seen in neurodegenerative conditions like AD. The
ICD of TREM2 is generated by ADAM12 and γ-secretase-
mediated cleavage after its trafficking to the plasma membrane
(Wunderlich et al., 2013; Park et al., 2015). TREM2 ICD was
found to be increased in both wild-type and TREM2 R47H
expressing cells by MG132 treatment (Figure 4D), indicating
that TREM2 ICD is normally degraded by the proteasome
although the functions of TREM2 ICD are not yet known.
TREM2 ICD is highly elevated in R47H-expressing cells by
about 6-fold upon exposure to bafilomycin A1 (Figure 4E),
which suggests that the R47H mutation may cause TREM2 to be
trafficked differently than its wild-type counterpart, resulting in
the increased lysosomal degradation of TREM2 ICD.
Interestingly, the half-life of TREM2 in the ER, but not in the
Golgi, is increased by the R47H mutation (Figure 5). This may
be the result of an impaired retrotranslocation of TREM2 R47H
from the ER due to glycosylation or structural changes. Since the
unglycosylated form of TREM2 (Figure 5A, c, Figure 5B) is in
the ER membrane and not in the cytosol after retrotranslocation
from the ER (Figure 5C), proteasomal degradation itself seems
not to be impaired by the R47H mutation. It may therefore
be that the recognition and retrotranslocation of TREM2 is
made much more inefficient by the R47H mutation. This
however did not cause ER stress (Figure 6). The exact molecular
mechanisms underlying these features of TREM2 R47H
remain elusive at present and future studies will therefore be
necessary.
We demonstrate for the first time in our current study that
the biochemical and molecular features of TREM2 are altered
by an AD-associated R47H mutation, and that these properties
of this variant protein may contribute to the pathogenesis
of AD. We anticipate that the findings of our current study
will be a starting point to further understand and study the
biochemical characteristics of TREM2 and to possibly devise
a future therapeutic strategy for AD such as normalizing the
glycosylation status of TREM2 R47H.
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